ALT-803 is included in three ongoing myeloma-based trials: a phase I single agent dose-escalation study (NCT02099539) in RRMM and a phase II trial with elotuzumab and melphalan in high-risk MM patients following ASCT and infusion of enhanced NK cells (NCT03003728). Here, GPT is linked to plasma cell myeloma.